




Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors

Introduction

Conclusions

Introduction

Results

GFS784 is a novel EGFR-targeted ADC equipped with a panRAS(ON) inhibitor payload.